Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Docetaxel

🥰Excellent
Catalog No. T1034Cas No. 114977-28-5
Alias RP-56976, NSC 628503

Docetaxel (RP-56976), a semi-synthetic analog of paclitaxel, is a microtubule depolymerization inhibitor (IC50=0.2 μM) that attenuates the effects of bcl-2 and bcl-xL gene expression and exhibits apoptosis-inducing, anti-tumor activity.

Docetaxel

Docetaxel

🥰Excellent
Purity: 99.29%
Catalog No. T1034Alias RP-56976, NSC 628503Cas No. 114977-28-5
Docetaxel (RP-56976), a semi-synthetic analog of paclitaxel, is a microtubule depolymerization inhibitor (IC50=0.2 μM) that attenuates the effects of bcl-2 and bcl-xL gene expression and exhibits apoptosis-inducing, anti-tumor activity.
Pack SizePriceAvailabilityQuantity
25 mg$30In Stock
50 mg$39In Stock
100 mg$57In Stock
200 mg$82In Stock
500 mg$136In Stock
1 g$197In Stock
1 mL x 10 mM (in DMSO)$52In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Docetaxel"

Select Batch
Purity:99.29%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Docetaxel (RP-56976), a semi-synthetic analog of paclitaxel, is a microtubule depolymerization inhibitor (IC50=0.2 μM) that attenuates the effects of bcl-2 and bcl-xL gene expression and exhibits apoptosis-inducing, anti-tumor activity.
Targets&IC50
Microtubule:0.2 μM
In vitro
METHODS: Human lung cancer cells NCI-H460 were treated with Docetaxel (0.2-200 nmol/L) for 24-72 h, and cell viability was measured by MTS.
RESULTS: The IC50 of NCI-H460 to Docetaxel was 0.030 μmol/L at 72 h and 0.116 μmol/L at 24 h. [1]
METHODS: Human prostate cancer cells PC-3, DU-145 and LNCaP were treated with Docetaxel (0.5-4 nM) for 48 h. Apoptosis was detected by Flow Cytometry.
RESULTS: High-dose Docetaxel treatment significantly increased the proportion of Annexin V+ apoptotic cells. [2]
In vivo
METHODS: To detect anti-tumor activity in vivo, Docetaxel (5-10 mg/kg) and PD-1 inhibitor (200 μg/only) were intraperitoneally injected into CB17 SCID mice carrying mouse prostate cancer tumor RM-1 five times a week for ten days.
RESULTS: PD-1 inhibitor combined with Docetaxel had a synergistic effect on prostate cancer in mice, inhibiting the growth of prostate tumors, increasing the survival rate and reducing adverse effects. [3]
METHODS: To assay antitumor activity in vivo, Docetaxel (7.5-15 mg/kg, intratumorally injected IT twice weekly for six weeks; or 20-40 mg/kg weekly intravenously injected IV) was administered to C57BL/6 mice harboring HNSCC tumors HN30 or HN12.
RESULTS: IT Docetaxel improved overall survival and disease-free survival and reversed tumor growth. At equivalent dose levels, IT Docetaxel resulted in 26-fold higher peak tumor concentrations and 24-fold longer tumor exposure than IV treatment. [4]
Cell Research
NCI-H460 cells (4 × 10^3) were grown in 100 μl of DMEM medium containing serum per well in a 96-well plate. After 24 h, the cells were treated with docetaxel (0, 0.2, 0.63, 2, 6.3, 20, 63 and 200 nmol/L, respectively) for 72 h. Every treatment was triplicate in the same experiment. Then 20 μl of MTS was added to each well for 1 to 4 h at 37°C. After incubation, the absorbance was read at a wavelength of 490 nm according to the manufacturer's protocol. The IC50 calculation was performed with GraphPad Prism 5.0 software [2].
Animal Research
Docetaxel (0, 10, 20, 30, 40, 60, and 80 mg/kg per week) was given once a week for 3 weeks for mice. Because more than 30 mg/kg per week of the drug caused body weight loss in mice, 20 mg/kg per week of docetaxel was judged to be the maximum nontoxic dose. Docetaxel (20 mg/kg per week) was given to mice once a week for 3 weeks at one of the following different points (2, 10, 14, or 22 HALO). Seventy-two hours after the final dosing of the agent, the intestinal mucosa of the small intestine (proximal 8 cm) was removed, fixed in 20 N Mildform solution (containing 8% formaldehyde in a buffered solution), and embedded in paraffin blocks, and sections of 5 mm were put on glass slides. Apoptosis was detected using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method, using the Apop Tag Peroxidase In Situ Apoptosis Detection Kit. Specimens were dewaxed and immersed in phosphate-buffered saline for 5 minutes at room temperature, incubated with 20 mg/ml proteinase K for 15 minutes at room temperature, and then quenched of endogenous peroxidase in 2% hydrogen peroxide in phosphate-buffered saline. Terminal deoxynucleotidyl transferase enzyme was applied directly onto the specimens, which were then incubated at 37°C for 1 hour. The reaction was terminated by transferring the slides to stop/wash buffer for 10 minutes at room temperature, and then specimens were covered with peroxidase-conjugated anti-digoxigenin antibody and incubated for 30 minutes at room temperature. Specimens were then soaked in staining buffer containing 0.05% diaminobenzidine to achieve color development. Finally, the specimens were counterstained by immersion in Mayer's hematoxylin solution. Apoptotic cells were counted under a light microscope in a good longitudinal crypt section. Starting at the base of the crypt column, the TUNEL-positive cells were counted up to the 18th cell position in each crypt.One hundred crypt sections were scored in each animal, and a frequency of TUNELpositive cells per crypt was calculated. Dosing time-dependent influence of docetaxel on intestinal apoptosis was also examined in female Balb/c mice [5].
AliasRP-56976, NSC 628503
Chemical Properties
Molecular Weight807.88
FormulaC43H53NO14
Cas No.114977-28-5
SmilesO(C(C)=O)[C@]12[C@]3([C@H](OC(=O)C4=CC=CC=C4)[C@@]5(O)C(C)(C)C([C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@]1(OC2)[H])=C(C)[C@@H](OC([C@@H]([C@@H](NC(OC(C)(C)C)=O)C6=CC=CC=C6)O)=O)C5)[H]
Relative Density.1.38 g/cm3
Storage & Solubility Information
Storagekeep away from direct sunlight,keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
Ethanol: 80.8 mg/mL (100 mM)
DMSO: 60 mg/mL (74.27 mM)
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 8.08 mg/mL (10 mM), In vivo: Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
Solution Preparation Table
DMSO/Ethanol
1mg5mg10mg50mg
20 mM0.0619 mL0.3095 mL0.6189 mL3.0945 mL
50 mM0.0248 mL0.1238 mL0.2476 mL1.2378 mL
Ethanol
1mg5mg10mg50mg
100 mM0.0124 mL0.0619 mL0.1238 mL0.6189 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Docetaxel | purchase Docetaxel | Docetaxel cost | order Docetaxel | Docetaxel chemical structure | Docetaxel in vivo | Docetaxel in vitro | Docetaxel formula | Docetaxel molecular weight